-
ERa ChIP-seq in breast healthy, primary cancer and metastatic tissues
Dataset
EGAD50000000642
-
Hi-C in breast healthy, primary cancer and metastatic tissues
Dataset
EGAD50000000643
-
DELFI low-coverage WGS of plasma cfDNA
Dataset
EGAD50000000630
-
Time series analysis of neoadjuvant chemotherapy and bevacizumab treated breast carcinomas reveals a systemic shift in genomic aberrations
Study
EGAS00001003287
-
BRCA1 secondary splice-site mutations
Study
EGAS50000000022
-
Personalized peptide vaccination among 173 patients with IDH wildtype glioblastoma: a retrospective analysis
Study
EGAS50000000449
-
Prognostic whole-genome and transcriptome signatures in colorectal cancers
Dataset
EGAD50000000169
-
WES and RNAseq dataset
Dataset
EGAD50000000337
-
Whole genome and transcriptome sequencing of cancer of unknown primary tumours
Dataset
EGAD50000000656
-
Non-KMT2Ar infant Acute Lymphoblastic Leukemia Sequencing
Study
EGAS50000000405
-
Prognostic whole-genome and transcriptome signatures in colorectal cancers
Study
EGAS50000000124
-
A single-cell multi-omic atlas of nodal B-cell non-Hodgkin lymphomas
Study
EGAS50000000342
-
Plasma mutation profile of precursor lesions and colorectal cancer using the Oncomine Colon cfDNA Assay
Dataset
EGAD50000000679
-
Integrating molecular imaging and transcriptomic profiling in advanced HER2-positive breast cancer receiving trastuzumab emtansine (T-DM1): an analysis of the ZEPHIR clinical trial
Study
EGAS50000000470
-
EC IO Data Access Committee UMCG
Dac
EGAC50000000334
-
Breast Cancer bulk RNA-Seq Dataset
Dataset
EGAD50000000649
-
DIAMOND PCR : plasma DNA LINE-1 targeted bisulfite sequencing, a new non-invasive multi-cancer detection marker
Dataset
EGAD50000000646
-
TSO500 STJAN33, BRAF mutated CUP
Dataset
EGAD50000000689
-
The dataset for Early detection of ovarian cancer using cell-free DNA fragmentomes and protein biomarkers
Dataset
EGAD50000000695
-
GIST Comprehensive Cancer Panel
Dataset
EGAD50000000548
-
Circulating tumor DNA dynamics reveal KRAS G12C mutation heterogeneity and response to treatment with the KRAS G12C inhibitor divarasib in solid tumors
Study
EGAS50000000315
-
First in vivo investigation of the impact of PARP inhibition with rucaparib alone and in combination with atezolizumab: results of the phase Ib COUPLET clinical study in advanced gynecologic and triple-negative breast cancers
Study
EGAS00001006100
-
Neoadjuvant immune checkpoint blockade in women with mismatch repair deficient endometrial cancer
Study
EGAS50000000483
-
Lactate metabolism in cancer stem cell fate regulation
Study
EGAS50000000063
-
SCLC MeDIP-seq
Dataset
EGAD50000000724